Effect of the estrogen antagonist, tamoxifen, on development of glomerulosclerosis in the Cohen diabetic rat.
Long-term administration of the estrogen antagonist, tamoxifen, to female, Cohen diabetic rats caused a significant decrease in the incidence of glomerulosclerosis, 12.5% as compared with 58.3% in control, untreated, diabetic female rats. This change in incidence was correlated with a corresponding decrease in plasma estradiol and cholesterol levels, but not with changes in oral glucose tolerance or insulin response. A similar correlation between decreased incidence of glomerulosclerosis and a decrease in plasma estradiol was previously noted in ovariectomized animals.
D000818:Animals; D002369:Castration; D002784:Cholesterol / Q000097:blood; D003928:Diabetic Nephropathies / Q000473:pathology / Q000517:prevention & control*; D004958:Estradiol / Q000097:blood; D005260:Female; D005951:Glucose Tolerance Test; D007328:Insulin / Q000097:blood; D007668:Kidney / Q000473:pathology; D007678:Kidney Glomerulus / Q000473:pathology; D051381:Rats; D013629:Tamoxifen / Q000627:therapeutic use*
D007328:Insulin; D013629:Tamoxifen; D004958:Estradiol; D002784:Cholesterol